Avid Bioservices Inc (CDMO)

[cjgaddy]

The new PPHM/ImmunoVaccine collab via AACR’17: looking at IV’s website https://www.imvaccine.com , it’s clear preclin. work has been done combining their “DepoVax” drug with PPHM’s Anti-PS, either Bavi or Fully-Human Bavi (PGN635=1N11), or the “Duke” B2GPI-indep. mab PGN632=11.31, or maybe even BetaBodies? We’ll probably find out 3-1-17 when the AACR’17 full abstracts are released.

ImmunoVaccine’s DepoVax Platform https://www.imvaccine.com/depovax.php
“The cornerstone of all vaccine dev. efforts at Immunovaccine is the company’s DepoVax vaccine adjuvanting platform. DepoVax is a patented vaccine delivery formulation that provides controlled & prolonged exposure of antigens + adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.
DEPOVAX IN CANCER:
Maintains remission and combats micro-metastases
*Provides strong & sustained polyfunctional T cell responses
*Specifically targets tumor cells”

= = = = = = = = = = = = = =
Apr1-5 2017: AACR 2017, WashDC http://tinyurl.com/jxfm3hb
PPHM+IMMUNOVACCINE:
AACR’17 4-4-17/8am #3657 - Session: BITES BISPECIFICS & CHECKPOINTS
”Phosphatidylserine-Targeting Antibodies Enhance Anti-Tumor Activity of a Tumor Vaccine in a HPV-Induced Tumor Model”
=> Genevieve Weir 1, Tara Quinton 1, Jeff T. Hutchins 2, Bruce D. Freimark 2, Marianne Stanford (VP/Res., Immunovaccine)
1=Immunovaccine, Inc., Halifax, NS, Canada [ https://www.imvaccine.com ]
2=Peregrine Pharmaceuticals

POSSIBLE GENESIS OF IMMUNOVACCINE COLLAB???
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”